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ABSTRACT 
 
Leishmaniasis is a world wide spread disease, it is an endimic health problem in more than 
88 countries and threatens over than 350 million people in the world. Leishmania parasite 
is transmitted to vertebrates by the bite of infected female sand fly. The disease exists in 
three different forms: 1) Visceral Leishmaniasis (VL) or Kala-azar, 2) Cutaneous 
Leishmaniasis (CL), 3) Mucocutaneous Leishmaniasis (ML).  
 
The main aim of the current study is to identify immunoreactive leishmanial epitopes using 
M13 phage display library for identifying peptides that mimic some naturally existing 
leishmanial antigens. Phage display was done by plaque assay in 12 amino acid peptide 
phage library. For phage screening purposes sera were collected from  individuals infected 
with  VL or CL, high antibody titer sera from different patients were pooled after screening 
for anti-Leishmania crude antigens by Enzyme Linked Immuno Sorbent Assay (ELISA). 
 
By the aid of the high antibody titer anti- VL pooled sera, two screening cycles of M13 
phage display library (12 amino acids peptide) were achieved. In the first screening cycle 
41 plaques were obtained and 54 plaques were obtained after the second screening cycle. 
From the 54 plaques, 35 plaques that gave the strongest signals with VL pooled sera were 
selected for further analysis. The DNA coding the 12 amino acid peptide fused with the 
PIII M13 phage gene was amplified using specific primers flanking the peptide designed 
based on the PIII gene. DNA sequence determination was performed for 15 different 
clones, followed by bioinformatics DNA analysis by means of DNA alignment and 
BLAST search analysis. From the 15 sequenced peptides 4 clones (namely Ph3, Ph23, Ph5, 
and Ph19) showed high similarity with Leishmania infantum and other Leishmaina species 
 v 
together with other flagellated protozoan parasites mainly Trypanosoma and Trichomonus 
species. Since the peptides are inserted in known location in the PIII gene of the M13 
phage; with known starting and final amino acids, the peptide sequence for the four 
mentioned clones was translated; and two clones (Ph3 and Ph23) showed high similarity 
with Leishmania infantum  epitopic regions. These findings strongly recommend to 
conduct further experimental analysis including synthesis of the two identified peptides 
and to evaluate their prospective use for diagnostic purposes or vaccines for VL.  
 vi 
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Chapter One: Introduction 
 
1.1 Background 
 
Leishmania, members of the protozoan family Trypanosomatidae, are obligate intracellular 
parasites that cause disease in human and animals. Leishmaniasis affects 12 million men, 
women and children in 88 countries around the world, over 350 million people are at risk, 
and over 2 million cases emerge every year (1). Leishmaniasis occurs in many parts of the 
world including parts of Europe, Asia, Africa, and the Americas. Leishmania parasites 
infect macrophage of verify of humans and mammalian reservoirs and it is transmitted by 
the bite of different species of infected female sand fly (Fig.1) leishmania parasites are 
exist during life cycle in two basic forms, promastigotes (flagellated extracellular stage, 
which are easy to grow in culture) that develops and transmitted by the sand fly, and 
amastigote (intracellular stage) that reside and multiplies in phagolysosomal vesicles of the 
macrophages in mammalian hosts(1, 2, 3). 
 
1.2 Life cycle 
 
Leishmania life cycle of the parasite by inoculation of the promastigote form into the skin 
by female Phlebotomine sand flies that transmit the disease, the parasites are internalized 
by dendritic cells and macrophages in the dermis and transform into amastigotes by losing 
their flagella. They multiply and survive in phagolysosomes through a complex parasite–
host interaction. The parasites in VL disseminate through the lymphatic and vascular 
systems and infect other monocytes and macrophages in the reticulo-endothelial system, 
resulting in infiltration of the bone marrow, hepatosplenomegaly and sometimes enlarged 
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lymph nodes (lymphadenopathy), whereas; in case of CL the parasite remained close to the 
inoculation site (3,4) (Figure. 2). 
 
 
igure 1: Female Phlebotomus (Adapted from CDC) 
 
 
Figure 2: Life cycle of leishmania parasite, adapted from CDC.
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Infection with leishmaniasis species can result in three main types of disease depending on 
the species, geography region and host immune response, the three main forms of disease 
are visceral leishmaniasis(VL) or Kala-Azar caused by Leishmania infantum and 
Leishmania donovani, Coetaneous leishmaniasis(CL) caused by Leishmania major, 
Leishmania tropica, Leishmania aethiopica in addition to Leishmania braziliensis and 
Leishmania mexicana in new world, Mucocutaneous leishmaniasis(ML) primarily caused 
by Leishmania braziliensis braziliensis does not heal.(3,4,5,6). Most infections in 
Leishmania exist as zoonoses amongst wild animals, such as rodents and dogs, and are 
prevalent in rural of forest areas and new world, while man is usually an incident host (3). 
Globally, there are an estimated 1.5–2 million new cases; and 70 000 deaths each year, and 
350 million people are at risk of infection in 88 different countries (1,4). Around twenty 
different species of Leishmania parasite are capable of infecting humans(1) 
 
1.3 Cutaneous leishmaniasis  
 
Is considered as a public health problem in many developing countries worldwide (1,3) and 
is endemic in the tropics and subtropics areas (1,7), is generally a mild disease in man with 
incubation period of one to 12 weeks (3,7,8), has extensively studied in both humans and 
mouse model systems (3). the parasite is confined to the skin(8) so it is usually called self –
limiting skin disease, usually on exposed parts of the body such as the face, arms or legs 
(fig. 3) (3,8,9), appears as either single or multiple lesions varying in size (3,9,10). The 
lesion is limited to a single part of the skin (localized cutaneous leishmaniasis) or may 
produce a large number of lesions (diffuse cutaneous leishmaniasis) (3,10). The 
appearance of these lesions is like volcano, with (a raised edge and central crater) (Fig.3), 
some of them are covered by a scab (8,11). Cutaneous leishmaniasis can be divided into: 
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New World disease, primarily caused by Leishmania braziliensis complex and L. mexicana 
complex, and Old World disease (Table.1), primarily caused by L. major, L. tropica, and L. 
aethiopica (3,7,8,11), Some Leishmania species are closely linked to humans so it found in 
cities (e.g., L. tropica), whereas some associated with animal species (zoonoses) so it more 
traditionally (e.g., L. major).  
 
 
 
Figure 3: Cutaneous Leishmaniasis 
 
Table. 1: Geographic distribution of Leishmaniasis species in the old world. 
 
Leishmania Species Geographic distribution 
L. major Middle East, Indian Subcontinent, northwestern China, Africa 
L. tropica Middle East, Indian Subcontinent, Western Asiatic areas. 
L. aethiopica East Africa, Yemen 
L. infantum Mediterranean basin 
L. donovani Sudan, East Africa, Asia 
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1.4 Mucocutaneous leishmaniasis 
 
Is life threatening in contrast of CL where it  causes a lesions at site of infection that can 
lead to partial or total destruction of the mucous membranes of the nose, mouth and throat 
cavities and surrounding tissues(fig. 4) with incubation period about 2-6 months or longer. 
Relapsing may act within 10 years, it caused by Leishmania species of the Viannia 
subgenus (Leishmania. (V) braziliensis, Leishmania (V) amazonensis, Leishmania. (V) 
panamensis, and Leishmania (V) guyanensis (9,12,13) but the ML that caused by L. 
braziliensis braziliensis is not heal (9) 
 
 
 
Figure 4: Mucocutaneous leishmaniasis 
 
1.5 Visceral leishmaniasis (kala-azar) 
 
Is a systemic disease and may be causes death if not treated, so it is considered as the most 
dangerous of the three manifestations of disease (1,5,14,15), whereas; The parasites invade 
bone marrow causing the immune system to weaken and increasing a person’s 
vulnerability to infection and disease. The risk for co-infection with AIDS is also rising. 
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VL caused by two Leishmanial species, L. donovani or L. infantum, depending on the 
geographical area, where L. infantum infects mostly children and immunosuppressed 
individuals, whereas L. donovani infects all age groups. VL causing chronic fever, weight 
loss, splenomegaly, hepatomegaly, and anemia (fig. 5). (3,6,16,17,18) it endemic in 65 
countries about 90% of cases found in poorest areas as Bangladesh, Brazil, Ethiopia, India, 
Nepal and Sudan with 100,000 death case each year (1,17). VL classified into two types 
according to transmission way: zoonotic VL found in area of L. infantum it transmit from 
animal to vector to human and anthroponotic. VL found in area of L. donovani it transmit 
from human to vector to human (6,18,19), the major reservoir for L. infantum(chagasi) are 
dogs, some types of this species of VL may cause CL in humans (21). In some studies the 
Leishmaniasisi classify into four types instead three, whereas in some patients of VL after 
recovery the disease may develop into Post-Kala-Azar dermal leishmaniasis(PKLDL) that 
requires prolong and expensive treatment(1,5,6), PKLDL is syndrome that develop after 
VL relapsing, whereas it appears as skin lesions that prominent on the face, may be the 
patients with chronic PKLDL could be a considered as reservoir host so they play a role in 
VL transmission(1,5,6). 
 
 
Figure 5: patients with visceral leishmaniasis adapted by WHO 
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1.6 Diagnosis and identifications 
 
The first Diagnosis of leishmania classically by symptoms and direct microscopy through 
detection of amastigote stages by Giemsa-stained smears. Also it is possible to use 
culturing methods of promastigote originated from Leishmania amastigote stage isolated 
from bone-marrow, lymph nodes or spleen aspirate (15,19), all these methods are 
considered as a classical methods and have disadvantages as in microscopic, it lack 
sensitivity, in cultures technique is time consuming and have contamination risk (19). 
Also, serological and molecular diagnostics approaches were followed, serological test 
based on direct agglutination test (DAT) with sensitivity of 94% but specificity only 72%, 
or immuofluorescence (IFA) and ELISA that using a recombinant antigen of parasite lysate 
(18,19). The use of whole parasites or its lysate in diagnosis did not showed high 
specificity to the disease. Western blotting techniques have been used to identify antigens 
for the specific and sensitive serodiagnosis of VL. One antigen, rk39, is a 39 amino acid 
repeat that is part of a kinesin-like protein expressed by L. chagasi tissue amastigotes (19). 
Recombinant k39 (rk39) was used in an ELISA as well as in a rapid 
immunochromatographic dipstick test (15,18,19) for the serodiagnosis of VL patients with 
active disease, with HIV co-infection, and after successful treatment (15,17,18). 
 
Developing rapid, inexpensive, sensitive and specific diagnostic tests approach based on 
molecular diagnosis was adopted by many researchers (15,18). A number of PCR assays 
have also been developed over the years for the detection of Leishmania DNA in a variety 
of clinical samples such as skin biopsies and smears, bone marrow and lymph node 
aspirates and peripheral blood. Nevertheless, there is no “unified” Leishmania PCR 
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available yet and the application of PCR as a routine diagnostic method is still limited by 
the mandatory technical expertise and equipment required. 
 
1.7 Treatment 
 
The main goal of Treatment of (CL) is inhibition of amastigote growth and the reduction of 
lesion size. In general; new world leishmaniasis is more sever with long lasting compared 
to old world that is heal spontaneously. Leishmanial lesions can be removed by traditional 
skin treatments including: cryotherapy, thermotherapy, electrotherapy, and surgery 
(7,8,11). Of the most famous chemical treatments is the use of paromomycin, pentavalent 
antimony, and amphoteracin B. The most common treatment is pentavalent antimonial 
derivatives sodium Stibgluconate (Pentostam) developed with meglumine antimoniate in 
the 1940s, their mode of action is inhibit the glycolysis and fatty acid oxidation of 
leishmania. Amphotericin B is a second line treatment using when pentostam is ineffective 
(WHO/ 2002,7,8,9,11,13).  
 
1.8 Epidemiology of leishmaniasis: 
 
1.8.1. Globally: 
 
The disease is endemic in 88 countries (66 are found in old world and 22 in new world), in 
southern Europe, central and south America, Africa, the middle east and south Asia (WHO 
1991, 1996, 1998, 2003,3,4,7,9). Today, an estimated 10-15 million individual have 
leishmaniasis all over the world, approximately 350 million at the risk of infection, and 
there is a new 1.5- 2 million cases each year (1,7,9). In case of CL an Estimation of 1-1.5 
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million of CL each year, 90% occurs in seven countries: Afghanistan, Algeria, Brazil, Iran, 
Peuro, Saudi Arabia and Syria in old world and Brazil and Peuro in the new world, around 
(7,9,16,). There are about 500,000 new cases of VL with 70,000 death each year, 90% 
occur in India, Bangladesh, Nepal (form 1-3%), Sudan, Kenya (form 50%) and Brazil 
(WHO 1991, 1996,4,6). 25-33% of new cases of CL comprised with VL. (1,5,7,9). 
 
1.8.2. Locally: 
 
Although and before many decades Cutaneous leishmaniasis clinical features were called 
“Jericho sore” but till now there is no comprehensive study that definitely indicate the 
Leishmanial causative species, the transmitting Phlebotomine vector, and the incriminated 
reservoir host in Jericho city. Only two epidemiological studies were performed on Jericho 
city, the former of them showed that 26.3% out of 190 individuals were sero-positive for 
Lesihmaniasis by ELISA test (20). The authors related the positive cases of CL to L. major 
without further parasitological studies that confirm the causative Leishmanial species. One 
year later and in another study; CL cases in Jericho were related to L. major and L. tropica 
species (20). In this study Leishmanial species were analyzed by ITS-PCR technique 
followed by endonuclease HaeIII digestion and showed out of the 156 CL examined 
samples 81cases(51.9%) were due to L. major infection, while 72 cases (46.1%) were 
related to L. tropica, and two samples were not identified (21). Since that time there is no 
studies and there are no evidence that indicating the species of the transmitting sand fly or 
the reservoir host in Jericho city. The clear transmission of Leishmanial parasite by 
Phlebotomus papatasi among their animal reservoir hosts and then its anthropophilic 
transmission from animals to humans is yet not studied in this area.  
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Regarding the prevalence of L. infantum the causative agent of VL in Palestine, reports of 
Palestinian Ministry of Health (PMOH) indicated that VL is located in southern and 
northern parts of the West Bank with high prevalence rate in the Hebron and Jenin districts 
and in the Bal’a village in north western Tulkarem city, all cases in children less than 9 
years old with annual incidence of 3.02/100,000 child (22,23). 
 
1.9 Immunity 
 
Leishmania parasite transmitted to the person through the bite of female sand fly, the effect 
of it on victim can be influenced by immunity status of the host so it depending on both 
innate and adaptive immunological response. The first target cells faced leishmania 
parasite are macrophage cells in skin or in visceral organs depends on Leishmanial species. 
So with regard to the fact that macrophages are the major host immune defense mechanism 
against Leishmania, infected macrophages are activated by Interferon- produced by T-
cells that mediate acquired resistance to leishmaniasis (24, 25, 26, 27).  
 
IL-12 required for initiation of the infection by development of Th1 cells and maintain 
resistance to leishmania, and this because IL-12 enhances IFN- production by Th1 cells; 
in absence of IL-12 the IL-4 produced by Th2 cells, this called Th1/Th2 paradigm 
(24,25,27,28,29,30,31,32,33). Previous studies(1994,1997) described that the activation of 
Th1 cells are associated with cellular immune response that develop protection through 
production of IFN--activated infected macrophages to produce nitric oxide to kill the 
intracellular replicating amastigotes. IL-12 considered as the important cytokine between 
innate immune response and acquiring protective Th1 cellular response specially in CL, 
whereas in VL and ML appeared insufficient production of Th1 cytokines to control the 
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infection (33,34,35,36,37,38,39,40). CD
+
8 cells have two mechanisms in protection against 
Leishmainia: producing cytokines as (INF- and TNF-α) or by killing the infected cells 
directly by Cytotoxic T-lymphocyte (CTL) – mediated mechanism (40,41,42,43). In case 
of B cells and antibody response considered not have a critical role against leishmania that 
hide inside the cells but have correlation with pathology since IgG induce IL-10 that 
promote the infection, humoral immune response appears in patient with VL, where they 
have a predominant IgG antibodies (39).  
 
1.10 Antigens of Leishmania 
 
Detecting of specific anti-Leishmanial antibodies is needed to know the antigen that evoke 
the immune response whereas the correct diagnosis of Leishmaniais essential to select the 
specific therapeutic approach (37,38,39,40). Several antigens of Leishmania species were 
identified and were used for diagnostic purposes, Parasite expressed antigens play 
important role in mediating Leishmania infection, rehearses Detecting specific anti-
Leishmanial antibodies need know the antigen that evoke the immune response. So in the 
last decade, several Leishmania antigens characterized to diagnose of Leishmania and 
develop vaccine and advanced methods of diagnostic with high sensitivity and specificity, 
whereas the correct diagnosis of Leishmaniais essential to select the specific therapeutic 
approach(40,44,45,46,47). several antigens were discovered and characterized genetically 
and antigenically in Leishmania species that used in diagnosis, whereas immunodiagnostic 
methods use whole promastigotes as antigen source. 
 
rK39 is a recombinant antigen used to diagnose VL caused by L. donovani, L. infantum 
and L. chagasi, it is predominant in L. infantum and L. donovani tissue amastigotes so 
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rK39 used to diagnose L. infantum, L. donovani and L. chagasi although it firstly derived 
from L. chagasi as a super family of motor proteins(19,43,44), derived from a 39-amino 
acid repeatitive immunodomenant B-cell epitope of the 230KDa LcKin protein 
(19,43,48,49), but the seroreactivity of rK39 relates with active disease, whereas it is 
highly sensitive and specific for acute VL diagnosis so used for the development of strips 
test, but it’s sensitivity limited in endemic area(19,43,49). There is no reactivity with other 
pathogens or to one Leishmania species as Cutaneous leishmaniasis.(49). Recently, new 
related hydrophilic antigens of recombinant antigens of L. chagasi cloned and 
characterized to use in serodiagnosis of VL. rK9 and rK26, rK26 differ in presence of 11 
copies of a 14- amino- acid repeat in the open reading frame(49,50,51). rK26 also specific 
to VL but it not tested as rK39(no other recombinant leishmanial protein has been 
tested(19,44,52). rK39 dipstick is only available rabid test for diagnostic Leishmania 
(WHO, 2009), according to several studies; the rK39 is the most suitable antigen for 
serological diagnosis followed by rK9 and rK26. 
 
Leishmania. major also as most leishmanial species express surface protein that play 
important roles in mediating leishmania infection. Two major classes of membrane 
antigens identified on the surface of the leishmania parasite; a family of glycolipids (LPG) 
and a family of glycoprotein gp63 and PSA-2 were well characterized in L. major, LPG, 
gp63 and gp46 expressed in promastigote stage and contribute in host-parasite interaction 
and disease pathogenesis (53,54,55,56). 
 
LPG consisting of lipophosphglycan (LPG) involved in parasite attachment to host 
macrophages and initiation of infection.  
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Gp36 is major surface glycoprotein, it is zinc-requiring actoprotease which anchored on 
the surface of Kinetoplastid of Protozal parasites of the genus of leishmania consist of 63 
KDa surface protein expressed with more than 500.000 copies it distributed over 
promastigote, some highly expressed in long-phase promastigote or in stationary phase 
promastigotes, so it described as major protease (leishmanolysin) because it mediate the 
entry mechanism into macrophages, inducing phagocytosis and survival in macrophage, 
Gp63 is also present in amastigote (53,54). This protease active molecule play a main role 
in resistance of complement-mediated lysis, so it is a candidate molecule for vaccination ( 
53, 54). The role of gp63 in L. amoazonesis was examined experimentally and was 
identified to play role in binding and survival of promastigotes within host macrophages. 
Macrophage binding could be mediated in two ways: (i) indirectly, through the 
complement component C3bi, which, after being generated from C3b by gp63 protease, 
attaches to the complement receptor on macrophage; here C3bi acts as a bridge between 
gp63-bearing promastigotes and the macrophage; and (ii) gp63 binds directly to an integrin 
receptor on the macrophage (24, 53). 
 
PSA-2: (Parasite Surface Antigen 2 family of proteins), which is another surface protein, 
belongs to a family of genes, which are highly polymorphic and produce multiple mRNA 
transcripts (56). These complex gene loci and its protein products have been detected in all 
Leishmania species examined except L. braziliensis. The function of PSA-2 play role in 
prophylactic immunization by encoding into plasmid DNA, also PSA-2 is effective in 
vaccination (11,56). However, areas of PSA-2 show similarity to Trypanosome cruzi and 
human mucins and to Drosophila glu protein, suggesting a possible role in protein- protein 
interaction. L. major PSA-2 has been shown to protect vaccinated mice subsequent to 
challenge with parasite by a Th1 type immune response (24, 56) 
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In addition there are other several proteins present in VL and CL evoke antibodies 
response; such as proteoglycolipid complex expressed by amastigotes P8 PGLC (55) 
Leishmania. major stress inducible1 (LmSTI1) protein (57), Leishmania thiol-specific 
antioxidant (TSA) protein (57), specific amastigote L. donovani A2 proteins, repetitive 
sequence of L. major gene B protein (GBP, for infective stage of leishmania). LmSTI1, 
GBP and HASPB1 can evoke antibodies in Post-Kala-Azar Dermal Leishmaniasis (PKDL) 
patients. While in ML the antibodies react with leishmania elongation initiation factor 
(LeIF) and KMPI1. The presence of IgM considered as early diagnostic marker (30) 
whereas the predominant antibodies in patients are IgG (55,57). 
 
1.11 Vaccination 
 
Leishmaniasis as any other disease needs to inducing immunity against re-infection. 
Development of vaccines need to understand the different immunological mechanisms 
against Leishmania and its expressed antigens. Nevertheless vaccination by the amastigote 
antigens are the most important antigens candidates since their antigens are exposed for 
longer time to host immune system (58,59,60,61,62).  
 
1.11.1. Leishmanization: 
 
Leishmanization is the oldest form of vaccination against Cutaneous leishmaniasis and has 
been practiced for over a century (58,61,62). Exudates from active lesions were inoculated 
into a covered part of the body of healthy children to induce a self-healing lesion and 
protection against multiple lesions on the face and other exposed parts of the body. This 
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approach later became known as “Leishmanization” (LZ) and live virulent promastigotes 
of Leishmania major harvested from cell free cultures of the parasite replaced inoculation 
from exudates lesions (62, 60, 63, 64, 61). Leishmanization use was later on limited due 
to:1) long-lasting skin lesions, 2) the spread of HIV (58,61,62,64).  
 
1.11.2. First generation vaccine (killed or fractions parasite): 
 
The first approach to developing a leishmaniasis vaccine was to use attenuated organisms. 
The ease of growing Leishmania in culture media made it possible to use promastigotes 
grown in vitro. Most vaccines used the L. amazonensis autoclaved lysate, while studies in 
the old world used autoclaved L. major antigen (58,59,60,61,63). 
 
1.11.3. Candidates for second generation vaccines: 
 
Live vaccines, genetically modified Leishmania species, and recombinant antigens are of 
the most important candidate second generation vaccines (58,60,61). These vaccines were 
started by having purified Leishmania sub-fractions such as the LiESAp-MDP, which is 
composed of the 54 kDa excreted protein of L. infantum plus MDP, protected dogs in a 
kennel assay against L. infantum infection, LiESAp vaccine induced protection against 
infection, but not against severe disease or death by VL.  
 
The second approach in second-generation vaccines is the use of recombinant proteins that 
were intensively tested since the 1990s. Of these antigens: the LeIF and HASPB1 proteins 
(58,61). Also, the TSA (thiol-specific antioxidant) and LmSTI1 (L. major stress inducible 
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protein 1), and LeIF (Leishmania elongation initiation factor) which are protective for mice 
and monkeys against CL (58,59,65) 
 
1.12 Random Peptide Phage Display Libraries 
 
An alternative approach for vaccine discovery is the utilization of phage display libraries. 
Epitope discovery by the aid of phage display technique is a new approach for identifying 
peptides or peptides that mimic protein and non-protein epitopes (66,67,68). The phage 
display describes a selection technique in which a peptide or protein is expressed as a 
fusion protein on the surface of filamentous phage resulting in display of the fused protein 
on the surface of the phage, while the DNA encoding the fusion resides within the phage 
(69). Phage display involves the production and screening of large numbers of random 
peptide sequences of a specific length (8-20 amino acids) expressed on the surface of 
phage particles (70). Phage display libraries have been used to study the binding specificity 
of numerous peptides and protein domains. Practical applications include the identification 
of peptide sequences that bind with high affinity to antibodies, enzymes or receptors, and 
may serve as diagnostics and vaccine or drug candidates (69,70.). Most phage display 
libraries consist of short peptides or protein fragments expressed on the surface of 
filamentous phage as N-terminal fusions to the pIII  or pVIII coat proteins(71). There are 
four or five copies of PIII protruding from one end of the phage particle, and up to several 
thousand copies of pVIII, the major phage coat protein. Both proteins are translocated 
through the bacterial membrane, where phage particles are assembled before exported into 
the periplasmic space. (72) 
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Several groups were able to produce different phage libraries, with random inserts of six or 
15 (70,73) amino acids. Using well-characterized monoclonal antibodies, it was shown that 
specific phage bearing specific sequence motifs could be isolated from these libraries. 
These libraries have been used for a variety of purposes, such as the mapping of antibody 
epitopes (73), development of novel enzyme substrates (74) and inhibitors (75), 
identification of recognition sequences on cell adhesion molecules (74), selection of high-
affinity DNA-binding zinc fingers (76), cloning of receptor ligand-binding domains (77). 
Phagotopes displaying the desired peptide can be isolated by affinity chromatography or 
biopanning on immobilized selector molecules. Selectors that have been used include 
antibodies, membrane receptors, enzymes, cultured cells, serum samples, and even the 
whole animal (77). 
 
Since peptide libraries almost provide an infinite source of molecular shapes, theoretically 
they include peptides that mimic epitopes of any antigen. Therefore, it becomes reasonable 
to investigate whether such small peptides can mimic carbohydrate epitopes. Using such 
libraries, small peptides have been identified that interact with the carbohydrate binding 
site of the lectin Concanavalin A (Con A) (78, 79). It was demonstrated that peptides 
containing the consensus sequence (YPY) bind Con A (78,80). Also, a peptide mimotope 
of the Lewis Y antigen was selected by screening a phage library using a specific mAb 
(79). Four residues (PWLY) were found to be critical for peptide binding to the antibody 
against the Lewis Y antigen, (79). 
 
So, one major application of random phage display peptide libraries is to determine the 
epitope of an antibody. Antibodies recognize small peptide motifs based on only three or 
four conserved residues (81). Based on the epitope motif identified by phage display, it is 
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possible to define the region of a protein recognized by the antibody. An antibody can 
either be directed against a linear amino acid sequence in a protein or a discontinuous 
epitope, which has a distinct conformation formed by the protein folding. Phage library 
screening with such antibodies has yielded peptides that mimic the structure of a folded 
protein. These ligands are called mimotopes (81). 
 
The pIII phage display library that was used in this study have peptides expressed at the N-
terminus of pIII coat protein of M13. The phage library was the Ph.D-12 random peptide 
phage library (New England Biolabs, Beverly, MA). Each phage expresses 12 different 
amino acids and in total the library contains 1.5 x 10
13
 pfu/ ml with a complexity of 2.17 x 
10
9
 transformants. 
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1.13   Objectives 
 
The main aim of this research is to identify immunoreactive leishmanial epitope selected 
according to the reactivity of high antibody positive sera (obtained mainly from visceral 
leishmaniasis patients and cutaneous leishmanisis patients) with different plaques assay of 
phage displayed library that contain millions of antigenic epitopes mimics some naturally 
existing leishmanial antigens. Bioinformatic analysis will be performed to determine order 
the DNA sequence of the selected epitope. The newly identified epitopes will serve as 
potential diagnostic markers of infection or they can be used in future leishmanial 
vaccination development. 
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Chapter Two: Methods And Material 
 
2.1 Leishmania stocks 
 
Several Leishmanaia species were used in this study (L. major, L. tropica, and L. 
infantum). The cultures were obtained from the WHO Leishmania references office from 
the Hebrew University. The Leishmanial species were brought in culture flasks containing 
promastigotes stages in M199 medium with (HEPS,10% FCS, Gentamycin and penicillin 
100mg\ml). Flasks were kept at 26˚C until antigen preparation. 
 
2.2 Antigen Preparation 
 
Leishmanial antigen was prepared for ELISA and Western Blot analysis according to the 
following procedure: Promastigotes of the L.  major, L.  tropica or L.  infantum were 
collected from 50 ml M199 culture containing at least 10
6
 parasites/ml by centrifugation at 
3,000 rpm for 10 minutes. The supernatant was completely aspirated and the parasite 
pellets were resuspended in 3 ml of lysis buffer (10 mM EDTA, 50 mM Tris, 50 mM 
NaCl, 0.01% SDS and PMSF Saint Louis protease inhibitors ( Sigma, USA)) incubated at 
4˚C for 30 minutes.  Protein concentration in the crude lysate was determined as indicated 
below. Parasite lysates containing crude antigen were frozen at -20˚C; crude antigen was 
thawed prior to its use in ELISA or Western blot.  
 
 21 
2.3 Protein Determination 
 
Protein concentration for the crude lysate antigen preparations was determined by Bradford 
macroassay using Coomassie Brilliant Blue G-250 dye according to standard method and 
to the manufacturer instructions (BioRad, Hercules, CA, USA). 
 
2.4 Enzyme Linked Immunosorbent Assay (ELISA) 
 
96-well microtiter plates were coated with leishmanial antigen (50 ul/ well) and incubated 
for 24 hours at 4˚C, plates were washed 3 times with phosphate buffered saline with 0.05% 
Tween-20 (PBS-T), blocked with 200 ul/well of PBS-T + 5% FCS or BSA and incubated 
for 30 min at room temperature, washed 3 times with PBS-T, 100 ul of serially diluted 
serum samples (starting from 1:100) were added as first Abs and incubated for 2 hours at 
37˚C, washed 3 times with PBS-T, 100 ul diluted protein A or HRP- conjugate (1:10000) 
was added as second Abs and incubated for 1 hour at room temperature, washed 3 times 
with PBS-T. color development was accomplished by adding 200 ul of the substrate- 
chromogen solution ( 1mg of the O-phenyldiamine to each 1ml of citrate buffer (PH 4.5) 
then 4 ul of the substrate (H2O2) was added to each 10 ml of the citrate buffer containing 
the chromogen and incubated for 30 minutes at room temperature, color development was 
measured at 360 nm by using ELISA autoreader. According to ELISA reader, the cutoff 
values and later the antibody titers were calculated.  Negative controls were included on 
each microtiter plate. 
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2.5 SDS-PAGE Gel Electrophoresis 
 
Lysates of L. major, L. donovani, L. infantum and L. tropica were seperated on 8% SDS-
polyacrylamide gels (SDS-PAGE) according to Garfin 2003 (82). Antigens lysates (10 l 
of 50g total protein) were mixed with 5l loading buffer (10% glycerol, 5% 2-ME 
(disulfide reducing agent), 5% SDS and 0.5M Tris PH 6.8 ), the mixture was boiled for 5 
min and loaded on the SDS-PAGE gel. The gel was run at 50v in stacking and 100v in 
seperating gel. Bio-Rad molecular weight markers (10-250 KDa) of low range were used. 
 
2.5.1. Coomassie Blue: 
 
Polyacrylamide gels were stained with comassie blue ( 1.25g coomassie blue R 250, 125ml 
methanol, 50ml acetic acid and 325ml D.W) for 15 min then destained ( 400ml D.W, 50ml 
methanol and 50ml acetic acid).  
 
2.5.2. Silver stain: 
 
The Polyacrylamide gel was fixed in 50% methanol minimum for one houre, washed 3X 
with D.W  for 5 minute each, stained with A-silver nitrate ( A- 0.8g nitrate stain was 
dissolved in 4ml D.W; B- 0.036g NaOH mixed in 10ml with 0.7ml ammonium hydroxide 
completed to 48ml with D.W, mixture A was titrated to mixture B, gel was stained with A-
B mixture for 15 minutes, the gel was washed 3X with D.W  for 15 min each, the gel was 
developed for 1-10 min in ( 1.25ml of 1% acetic acid mixed with 0.125ml of 38% 
formaldehyde made to 250ml with D.W) until the bands observed, developer was removed 
by D.W. 
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2.6 Western Blot Technique 
 
Western blot analysis was done according to Towbin, 1979 (83). Following SDS- PAGE, 
described above, the gel was equilibrated for 30 minutes in transfer buffer (0.025M Tris-
HCl, 0.192M glycin and 20% methanol). Proteins from polyacrylamide gel were 
transferred to nitrocellulose membranes (Whatman, USA). After transfer, the membrane 
was cut into strips and blocked with 5% skimed milk prepared in phosphate buffer saline 
with 0.1% Tween-20 (PBS-T) for 30 min at RT. After that; stripes were incubated for 2 
hours at room temperature with diluted 1:500  VL infected pooled sera in PBS-T solution. 
Unbound antibodies were washed 3X  for 5 minutes each with PBS-T and then seconding 
Abs (Protien A-HRP or anti-Human IgM-HRP) diluted in PBS-T (1:4,000) for 1 hour at 
room temperature. Excess secondary antibodies were washed off 3X for 5 min each with 
PBS-T. Bound antibodies on gel strips were detected with DAB stain (25 mg DAB in 25 
ml PBS, 0.05% H2O2), Strips were incubated for 15-30 minutes at room temperature until 
the color was developed.  
 
2.7 Phage Display Peptide Library: 
 
The øD. 12 peptide ø - display library Kit E8110S (New England Biolabs, Ipswich, MA, 
USA) was used, mainly according to the recommendation of the manufacturer with slight 
modifications; the specific used materials and protocols are described below. 
 Bacterial cells: E. coli ER2738 host strain 
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 Lauriabroth (LB) Medium: was prepared by dissolving 10 g Bacto-Tryptone, 5g 
yeast extract, 5g NaCl in double distilled water, autoclaved and stored at room 
temperature. 
 LB Plates: To 1 liter LB medium, 15 g bacto-agr was added, dissolved and 
autoclaved, and then poured in Petri dishes, plates were stored upside-down at 4°C 
until used (within 3 weeks). 
 LB top agar: To 100ml LB medium, 0.7g bacto-agr was added, the solution was 
prepared in 200ml bottle, autoclaved, and stored at 4°C until used. The molten top 
agar was equilibrated to incubated  50°C before use. 
 
2.7.1. M13 bacteriophage titration: 
 
M13 phage was obtained as part of the kit (phage display library NE, Biolabs, USA): 
1. 5ml of LB broth was inoculated with E. coli ER2738 from a freshly grown plate 
culture and incubated overnight with shaking 200 rpm. In the next day, a dilution of 
1:50 was made in 50 ml LB broth and cells were grown at 37
o
C with shaking 200 
rpm until reached mid-log phase, (OD600 ≈  0.5). 
2. While cells are growing, top Agar was melted in microwave and dispensed into 3 
ml in 15ml sterile culture tubes, one tube per each phage dilution. Tubes were 
maintained at 45°C. 
3. LB agar plates were pre-warmed, for at least one hour at 37°C until ready for use. 
4. Serial dilutions of M13 bacteriophage in LB (104 to 108-fold) were prepared in 1 ml 
LB final volumes.  
5. When the culture in Step 1 reached mid-log phase, 200 μl aliq-uots were dispensed 
into Eppendorf tubes, one for each phage dilution. 
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6. To carry out infection, 10 μl of each phage dilution was added to each Eppendorf 
tube containing the bacteria, mixed, and incubated at room temperature for 1–5 
minutes. 
7. Infected cells were transferred one infection at a time to culture tubes containing 
45°C top agar. Tubes were vortexed briefly and immediately poured onto a pre-
warmed LB plate. Plates were gently tilt and rotated to spread top agar evenly. 
8. Plates were incubated overnight at 37°C. 
9. Phage titer that allows growth of about 500 plaques per plates was used.  
 
2.7.2. M13 phage plaque assay: 
 
The M13 phage titer that gave about 400 to 500 plaques per plate was used along all the 
peptide screening assays. In each screening cycle about 10 plates 500 plaques/ plate were 
prepared as mentioned above in M13 phage titration, the obtained plaques were transferred 
onto nitrocellulose membranes as described below.  
 
2.7.3. Plaque lifts onto nitrocellulose membranes: 
 
The prepared M13 phage plates were chilled for 2 hours at 4°C to prevent the top agar 
from sticking to the nitrocellulose membrane. To each LB agar plate containing plaques a 
nitrocellulose membrane was placed over the plaques for 2 to 5 minutes to allow the 
transfer of the phage particles to the membrane. A needle soaked with waterproof ink was 
used in making prick through the membrane and agar for orientation. The membranes were 
removed from the plates and kept at room temperature for 1 hour to dry and to allow the 
binding of the phage particles to the membrane. The dried membranes were submerged in 
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phosphate buffered saline for few minutes then blocked with 5% BSA in PBS with 0.5% 
tween-20 for 30 min, then screened by VL high antibody titer sera as mentioned in 
Western blotting (see 2.6).  
 
2.7.4. Screening by normal human sera: 
 
All selected plaques that showed reactivity with VL collected sera were screened by 
normal human sera. All the analyzed clones of high potential as VL epitopic regions did 
not show any reactivity with normal human sera.  
 
2.8 Polymerase Chain Reaction (PCR) 
 
PCR reaction was carried out in a final volume of 25µl Ready Mix PCR tubes (Syntezza, 
Jerusalem). For each tube a 20 µl of sterile water containing 15 pmoles of each primer 
(reverse and forward) was added followed by the addition of 5 µl from each extracted 
DNA sample. The used PCR amplification protocol involving 5 min at 95
o
C, followed by 
35 cycles each of 30 seconds at 95
o
C, 30 seconds at 55
o
C (depends on the used primers), 
followed by 1 min at 72
o
C, and a final elongation step at 72
 o
C for 10 min.  
 
2.9 Agarose Gel Electrophoreses 
 
The PCR products were separated on a 1.5 % agarose gel in TAE buffer (Tris base, acetic 
acid and EDTA). The pUC 8 Mix Marker (Fermentase, Lithuania) was used for sizing PCR 
amplifications. 
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2.10 DNA Purification 
 
The PCR products were cleaned by Qiaquick PCR purification Kit (Qiagen, Hilden, 
Germany), according to manufacturers' instructions. In a few cases, where multiple bands 
appeared, these were excluded from this study. 
 
2.11 DNA sequencing 
 
Purified PCR products were sequenced according to dye terminator method, using 
Automated DNA Sequencer machine (AB477). Using the primers which were used for 
PCR amplification, for each PCR product forward primers were used in DNA sequences 
acquaint.  Obtained sequences were then aligned by using BLAST online service on Pub- med to 
determine homology.    
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Chapter Three: Results 
 
3.1 Enzyme Linked Immunosorbent Assay (ELISA) 
 
The collected serum samples from known Visceral and Cutaneous leishmaniasis infected 
individuals were examined by ELISA method for their reactivity against Leishmania 
parasite crude antigen. The antibody titers for the different tested serua samples were 
identified (Table 2), taking into consideration a cut-off value calculated based on local 
normal human serum samples. From the obtained results it is clearly seen that most of the 
examined VL cases have a higher antibody titer (1/1600) compared to CL cases that ranged 
from 1/100-1/800.  
 
Table 2: Antibody titers of the different tested sera based on ELISA test against L. 
donovani crude antigen. 
 
Sample No. Location Leishmaniasis Type Antibody Titer 
1 Jenin VL 1/1600 
2 Hebron VL 1/1600 
3 Jenin VL 1/1600 
4 Jenin VL 1/1600 
5 Jenin VL 1/1600 
6 Hebron CL 1/100 
7 Jericho CL 1/100 
8 Jericho CL 1/100 
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9 Hebron CL 1/100 
10 Hebron CL 1/100 
11 Jericho CL 1/100 
12 Jericho CL 1/100 
13 Hebron CL 1/100 
14 Hebron CL 1/100 
15 Jericho CL 1/200 
16 Jericho CL 1/200 
17 Jericho CL 1/200 
18 Jericho CL 1/200 
19 Jericho CL 1/600 
20 Hebron CL 1/800 
 
Serum samples of high antibody titers were pooled together, 5 samples of VL cases and 6 
samples of CL cases with antibody titers ranged from 1/200 to 1/800, the CL cases with 
low antibody titers (1/100) were excluded from the study. The main aim of the serum 
pooling strategy is to have larger volumes of starting anti-Leishmania antibodies that is 
sufficient for western blot and ø - display analysis to be conducted in this study.  
 
 30 
3.2 SDS-Polyacrylamid gel electrophoresis (SDS-PAGE) and Western blotting 
 
3.2.1. SDS-PAGE: 
 
Different Leishmanial crude extracts were analyzed by SDS-PAGE and Western blotting 
techniques. The extracts were prepared from whole cultured Leishmania parasite cells; 
extracts from L. major and L. tropica (the causative agents of CL) and L. infantum (the 
causative agent of VL).  From the prepared three extracts about 10g total proteins in 15l 
total volume were separated on SDS-PAGE. Four different gels were prepared; each 
containing the three different parasites’ crude extracts and MW marker. Two of the gels 
were stained with 1- Commasie blue satin (Figure 6), and 2- Silver stain (Figure 7). As 
seen in figure 6 and 7, that represent comparison between the proteins banding patterns 
from the three different crude extracts; relatively all the extracts have the same protein 
quantities. 
 
 
 
Figure 6: Commassie Blue-Stain of SDS-PAGE gel representing crude extract protein 
banding patterns from 1- L. major, 2 - L. tropica, 3- L. infantum. MW: molecular weight 
markers are indicated in KDa. 
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Figure 7: Silver-Stain of SDS-PAGE gel representing crude extract protein banding 
patterns from 1- L. major, 2 - L. tropica, 3- L. infantum. MW: molecular weight marker. 
 
3.2.2. Western Blotting: 
 
The reactivity of the three Leishmanial extracts was done by the aid of two high antibody 
titer serum pools, one was collected from VL infected individuals and the second from CL 
infected individuals as indicated in (3.1). For this purpose four SDS-PAGE gels were 
prepared, each gel contains extracts from L. major, L. tropica, and L. donovani species. 
Antibody reactivity from each tested serum pool was examined by anti-human IgM and 
anti-human IgG, this was carried out in order to determine the type of most reactive 
antibodies produced in infected individuals and later to determine the second antibody to 
be used in phage display screening protocol. Western-blot analysis of CL pooled sera did 
not showed any reactive antibody against any of the tested lesinmanial extracts (data not 
shown), while there was different reactivity pattern upon applying the pooled serum from 
VL infected individuals (Figure 8). Also, it is clearly seen that the major antibody class of 
the provoked antibodies against leishmanial antigens in human sear were of the IgG 
istotype (Figure 8-A), since using anti-human IgM as secondary antibody could not detect 
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any antibodies reactive against any of the leishmanial extracts (Figure 8-B), but using 
Staphylococcus/Streptococcus protein A (that has a high affinity only for IgG antibodies) 
identified several reactive bands from the three analyzed leishmnial species (Figure 8-A). 
The results indicate that there are specific antigenic determinants that can be detected by 
the collected VL pooled sera and this evoked antibody response was detected by the aid of 
secondary IgG antibodies or compatible molecules (i.e.: protein A). This step was 
important to enable planning for the screening of the phage library and to prove presence 
of a reactivity with VL or CL pooled sear against the different ø-D epitopes.  
 
 
Figure 8: Western-blot analysis representing the reactivity of VL collected pool serum 
against different leishmanial crude extract, 1- L. major, 2 - L. tropica, 3- L. infantum. In A: 
protein A-HRP was used as secondary antibody, and in B: anti-human IgM-HRP was used 
as secondary antibody. MW: molecular weight marker. 
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3.3 Phage display 
 
Phage library titration: The phage library titer was estimated to be 10
13
 plaque forming 
units (pfu)/ml, and this was in agreement with number supplies by the phage library 
manufacturer (New England Biolabs, Ipswich, MA, USA). The titer of the phage library 
decreased along storage time, for this reason and for obtaining a workable number of 
plaques in each plate; the phage library was titrated using different dilutions of phages 
starting from 10
-4
 down to 10
-10
. Each dilution was used to infect 0.1ml of freshly grown E. 
coli bacteria followed by plating on LB agar plate with minimal media components as 
indicated in the materials and methods. After performing this test it was found that diluting 
the phage up to 1:10
9
 is the titer that produces about 500 separated plaques per plate, this 
phage dilution was used all over the screening cycles in this study.  
 
3.3.1. Screening of Phage library with VL serum: 
 
Screening of phage library using the serum pooled from VL infected individuals was done 
at two cycles. In the first cycle, 10 plates containing M13 phage plaques were screened 
with 1:1000 diluted VL serum as first antibody and protein A-HRP as a secondary 
antibody, only the plaques that gave strong color signals were isolated. The obtained 
results of the first screening cycle were as shown in (Table 3):  
1. Plaques were only detected in 5 plates out of 10.  
2. Assuming the total number of plaques in each plate is 500, then only 41 out of 
5000 M13 phage plaques showed reactivity with VL pooled sera, which is less 
than 1% of the plaques.  
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Table 3: A summary of obtained M13 plaques after first and second screening with VL 
pooled sera of high antibody titer against leishmanial crude antigen. 
 
Plate number 
Screening 
cycle 
Used serum 
Number of 
obtained plaques 
Totals 
1 First VL 22  
 
41 
2 First VL 3 
3 First VL 4 
4 First VL 9 
5 First VL 3 
6 Second VL 11  
 
54 
 
7 Second VL 27 
8 Second VL 10 
9 Second VL 6 
 
The reactive plaques were marked and picked up from the agar plates and incubated in LB 
media with hst bacteria for further analysis.  
 
In the second screening cycle we supposed to grow of each the obtained plaque in a 
separate plate and to rescreen with VL sera, but because the limited amount of the VL 
pooled sera sample it was suggested to rescreen each five plaques together. So, bacterial 
cells were infected with a mixture of five plaques and this was followed by plating the 
phages on agar plates as indicated in materials and methods. Theoretically this approach 
aims to enrich the plate with many plaques of the same type, and it is recommended at this 
stage to grow the phages in a titer that gives a limited number of plaques per plate in order 
 35 
to enable easier isolation of independent plaques without overlapping each other. As seen 
in table 3, another 54 plaques were selected to be used for further analysis in this study. 
None of the selected plaques were reactive with normal human sera when they screened 
with 1:1000 diluted serum  pooled from normal human. 
 
3.4 M13 phage epitope identification 
 
From a total of 54 selected and purified M13 phage plaques that were chosen after two 
screening cycles with VL pooled sera, 35 different plaques were selected for sequence 
analysis and epitope mapping. The 35 plaques were selected based on their strong signals, 
obtained after reactivity of the bound protein-A-HRP to the human α-VL antibodies.  
Signal were judged strong based on the color intensity relative to other plaques. These 
plaques represent antibodies with a high affinity to M13 phage epitopes that mimics 
leishmanial epitopes. This part of the results shows the similarity of the obtained M13 
phage epitopes to already known leishmanial proteins or sequences in the Gene Bank data 
base and identification of some potential clones to express specific leishmanial epitopes.  
 
3.4.1. DNA amplification of the fused peptide/pIII M13 phage from the selected 
clones: 
 
It is known that the insertion of the random peptides in the pIII M13 phage gene to form a 
sequence of random peptide library pIII fusion peptides (Figure 9) (New England Biolabs, 
Ipswich, MA, USA). Based on this information of M13 phage library construction, and on 
the DNA sequence information of the pIII gene; a pair of primers were designed to enable 
a specific amplification of the fusion peptide (Figure 9). At the beginning, the PCR primers 
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were designed based on the provided information from the manufacturer company of the 
M13 phage library. At this stage; DNA was amplified using two primers that are flanking 
the peptide region and amplifying a DNA segment of 120 bp (Table 4).  
 
 
 
Figure 9: DNA and amino acid sequence information of the pIII-peptide fusion in M13 
phage. The sequence in the rectangular represents primers location (ø D1: at 5’end and ø 
R1: at 3’end).  
 
Table 4: Primers and their nucleotide sequence information that were used in amplifying 
the pIII-peptide fusion DNA fragment from selected ø-D library M13 phage.  
Using the primer combination ø D1 and ø R1 in PCR amplification of the fused peptides; 
could only amplify DNA segments from 10 clones out of the 35 selected clones (Figure 9). 
Phage primers Nucleotide sequence of primers 
Size of the amplified 
DNA band 
ø D1 TTA TTC GCA ATT CCT TTA GTG  
ø R1 ATG GGA TTT CGT AAT ACA AC  
Using PhD1 and PhR1 
(120bp) 
ø R2 TCC CTC ATA GTT AGC GTA ACG 
Using PhD1 and PhR2 
(245bp) 
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The amplified DNA segments were not suitable for DNA sequence analysis because they 
were very low in concentration and because their small size (120 bp) it was not possible to 
purify them out of the PCR primers. To solve this problem, another primers was designed 
based on the full DNA sequence information of pIII gene of the M13 phage that was 
retrieved from the Gene Bank (accession number gp AF031088) (Figure 10). The 
previously used forward primer was kept and a new reverse primer was designed that is 
located an additional 120 bp don in strum at 5’-end of the previous reverse primer. These 
PCR primer combinations (Ph D1 and Ph R2) were able to amplify a 245bp DNA segment 
that include the inserted peptide and the flanking region from the pIII gene. This PCR 
system was able to amplify the expected DNA segment from all the 35 selected clones 
(Figure 11). These selected clones were numbered from Ph1 to Ph35 according to their 
arrangement in figure 10. 
 
 
Figure 10: Agarose gel electrophoresis analysis of the amplified PCR products using Ph D1 
and Ph R1 primers targeting the fused peptide in pIII M13 phage gene in the 35 different 
selected clones.  
 38 
 
Figure 11: DNA sequence of  the pIII M13 gene with the site of the inserted DNA 
sequences. Based on this sequence forward primer (ø D2)  and a reverse primer (ø R2) are 
indicated. 
 
 
 
ggagcctttt ttttggagat tttcaacgtg aaaaaattat
tattcgcaat tcctttagtg gtacctttct attctcactc
T         Site of inserted peptide 
gctacttcg catctgcatg ttcggttgcc gtcgaagggt
ggaggttcgg ccgaaactgt tgaaagttgt ttagcaaaat
cccatacaga aaattcattt actaacgtct ggaaagacga
caaaacttta gatcgttacg ctaactatga ggga
5’-
- 3’
 
 
Figure 12: Agarose gel electrophoresis analysis of the amplified PCR products using Ph 
D1 and Ph R2 primers targeting the fused peptide in pIII M13 phage gene in the 35 
different selected clones.  
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3.4.2. DNA sequencing of the fused peptides pIII gene: 
 
From the 35 selected clones based on a second screening cycle with VL high titer pooled 
sera, 18 clones were chosen for further sequence analysis and later for peptide 
identification. Namely these clones were (Ph3, Ph5, Ph12, Ph19, Ph20, Ph22, Ph23, Ph24, 
Ph25, Ph27, Ph28, Ph29, Ph30, Ph31, Ph32, Ph33, Ph34, and Ph35). The PCR product 
amplified by the second primers combinations (Figure 12) for these indicated clones was 
purified and sent for DNA sequence analysis service to where. the nucleotide sequences 
poor Ph12 was not successfully sequenced, and this seems for to be caused by mixed PCR 
amplification products (Figure 12), also clones 31, 33, and 35 showed sequences with 
many unidentified nucleotides reflecting contamination of more than one clone in these 
PCR amplified products. So DNA sequence analysis was only performed for the remaining 
14 clones. 
Duplication PCR band amplification, as seen in gel, lanes 12,23,25,29 and 33 represent a 
mixed plaques due to presence of more than one plaques, or co-infection when performing 
library  
 
Figure 13 shows the DNA alignment of the obtained sequences using BLAST, identified 
nucleotides belonging to the inserted peptide.  The homology between all clones in the 
flanking regions that belongs to the pIII gene of the M13 phage is evident. For accurate 
similarity analysis among DNA sequences of the 14 different peptides; a second alignment 
was performed without the flanking regions and this in order to remove any extrinsic 
factors affecting the alignments (Figure 13). Based on the second DNA alignment; it was 
concluded that there is no similarity at the DNA level among all the obtained fused peptid ; 
each of these clones represented different epitope that needs more analysis.  
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DNA sequence information of the 14 inserted peptide-pIII M13 gene without the 
flanking region of the known pIII gene (Figure 14) is shown in appendix A.  
 
 
ph3     TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT------ACTCGTCAGAG 54 
ph19    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT------GATCATCATGG 54 
ph28    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT------CATATTACTAC 54 
ph5     TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT------AGTGTTCATAG 54 
ph22    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT---CATGGTATNTATGN 57 
ph24    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCTGGTCAGGGTAGTT---C 57 
ph25    TTATTCGCAATTCCTTTAGNGGNACCTTTCTATTCTCACTCT---CCGGATNNTTTTNC 57 
ph32    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT---AC------------ 45 
ph23    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT---AAGTATATGCATGC 57 
ph27    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT---G-GTGTGGTTACGC 56 
ph33    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT---AATATTCTTTATGC 57 
ph34    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT---TAGGATCTTTTGGC 57 
ph29    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT------ACGAATGAGAC 54 
ph30    TTATTCGCAATTCCTTTAGTGGTACCTTTCTATTCTCACTCT----TTGCCTCCTATGT 56 
ph20    TTATTCGCAATTCCNTTAGTGGTACCTTTCTATTCTCACTCT-------CTNCCTGNAT 53 
        *************** **** ** ****************** 
                  
ph3    TCGTAATTCTCATGA-TATGCGGGTG---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph19   G-ATGGTT--CATGC-TGATCGGATGATTGGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph28   GAGGACTAGTACTGT-TGAGCGGAAT---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph5    TGAGAGGAGTAAGTT-TCTGCGGAAT---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph22   --GNATAATNAGAC--TCAGAAGCCT---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph24   --GTTTGGGTAGAA--TATGAAGCTT---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph25   A-AANCCNANAGA---GGNACCGCCN---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph32   --ANCNNNAGAGG---CAGNNNCCNG---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 97 
ph23   --ACCTCT-TACGCC-GGCGCCTTCG---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph27   --ATCTTTATACGCC-TTTGCCGGCT---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph33   --AAATCATTAAAT--TGTTCCTAAT---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph34   --AATTCCTTTAGT--TGATCCTTTG---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph29   TCGTACTGTGCGGCA-TATTCGGTTT---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph30   --AGTTTAAGGTGGG-GGCGCAGTTT---GGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 110 
ph20   NGNAATCAGNAGACNAGGCNTAGTNT--TGGTGGAGGTTCGGCCGAAACTGTTGAAAGTT 111 
                                    ******************************* 
ph3    GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAAC-TCG-GAAAGACGA-NAAAAA 166 
ph19   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAAC-TTG-GAAAGNNGA-CAAA-- 164 
ph28   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAAC-TNT-GAAAGACGA-CAAA-- 164 
ph5    GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAAC-TNT-GAAAGACGA-CAAA-- 164 
ph22   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAACGTCGTGAAAGACGA-CAAA-- 166 
ph24   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAAC-TCG-GAAAGACGA-CAAA-- 164 
ph25   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAACGTCGTGAAAGACGA-CAAA-- 166 
ph32   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAACGTCGTGAAAGACGA-CAAA-- 153 
ph23   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAAC-TCG-GAAAGACGA-CAAA-- 164 
ph27   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAACGTCG-GAAAGACGAACAAA-- 166 
ph33   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAAC-TCG-GAAAGACGA-CAAA-- 164 
ph34   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAAC-TCT-GAAAGACGA-CAAAA- 165 
ph29   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAACGTCGTGAAAGACGA-CAAA-- 166 
ph30   GTTTAGCAAAATCCCATACAGAAAATTCATTTACTAAC-TCG-GAAAGACGA-CAAA-- 164 
ph20   GTTTAGCAAAATCCCATACAAANAATTCATTTACTAAN-TCN--GAAGAGGA-CAAA-- 164 
       ******************** * **************  *     ***  **  ***   
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Figure 13: DNA alignment of the obtained sequence information of the 14 different 
analyzed clones including the flanking regions of the pIII gene of M13 phage. Indicated 
with striks. 
 
Figure 14: DNA sequence alignment of the 14 different peptides, similarity sequences at 
5’-end represents histidin and serine amino acids and those at the 3’-end represents three 
glycine molecules. 
 
3.4.3. Bioinformatics and DNA sequence analysis: 
 
This part of the work involved similarity search to the obtained peptide sequences, this was 
done using BLAST online service provided through the PubMed /US National Institute of 
Health (http://www.ncbi.nlm.nih.gov/pubmed/).  
 
From the 14 examined peptide DNA sequences, only two clones showed similarity to 
Leishmania parasite DNA genomic sequences, clone Ph3 anPh23. Table 5 shows a 
summary of the most similar clones to Leishmania or other related protozoan parasites 
(such as Trypansosma and Trichomonus). Blast analysis of clone Ph3 showed a 34% of 
 
ph22   CACTCT---CATGGTATNTATGNGNATAATNAGACTCAGAAGCCT------GGTGGAGGT 51 
ph24   CACTCTGGTCAGGGTAGTT---CGTTTGGGTAGAATATGAAGCTT------GGTGGAGGT 51 
ph20   CACTCT---CTCTCTNCCTGNATN-GNAATCAGNAGACNAGGCNTAGTNTTGGTGGAGGT 56 
ph30   CACTCT---TTGCCTCC---TATG--TAGTTTAAGGTGGGGGCGCAGTTT-GGTGGAGGT 51 
ph3    CACTCT---TAC--TCGTCAGAGTCGTAATTCTCATGATATGCGGGTG---GGTGGAGGT 52 
ph19   CACTCT---GA---TCATCATGGG-ATGGTTC--ATGCTGATCGGATGATTGGTGGAGGT 51 
ph28   CACTCT---CATATTACTACGAGGACTAGTAC---TGTTGAGCGGAAT---GGTGGAGGT 51 
ph5    CACTCT---AGTGTTCATAGTGAGAGGAGTAA---GTTTCTGCGGAAT---GGTGGAGGT 51 
ph29   CACTCT---ACG---AATGAGACTCGTACTGTGCGGCATATTCGGTTT---GGTGGAGGT 51 
ph23   CACTCT---AAGTATATGCATGCACCTCT-TA--CGCCGGCGCCTTCG---GGTGGAGGT 51 
ph27   CACTCT---TGGTGTGGTTACGCATCTTTATA--CGCCTTTGCCGGCT---GGTGGAGGT 52 
ph33   CACTCT---AATATTCTTTATGCAAATCATTA--AATTGTT-CCTAAT---GGTGGAGGT 51 
ph34   CACTCT---TAGGATCTTTTGGCAATTCCTTT--AGTTGAT-CCTTTG---GGTGGAGGT 51 
ph25   CACTCT---CCGGATNNTTTTNCAAANCCNANAGAGGNACCGCCN------GGTGGAGGT 51 
            ******                                             ********* 
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this sequence has 100% similarity with Leishmania donovani and Leishmania infantum 
species, which are the causative agents of VL (Table 5). Also, and in another region of the 
peptide sequence that represents 34% coverage of the sequence, it showed 100% similarity 
with both Trypansosma and Trichomonus parasites. These parasites are protozoan 
flagellates and are closely related to leishmania family (Kinetoplastidae). This fact 
supports the potential identity of the Ph3 peptide as a Leishmanial epitope. An analogous 
result was also obtained for peptide Ph23, but it showed similarity to L. major and L. 
braziliensis. Other peptides (Ph5 and Ph9) showed similarity to related parasites with 
coverage between 51%-64%, and a minimum similarity of 95%.  
 
Table 5: Peptide DNA sequence similarity and coverage percentages with other 
related species. 
 
Clone Similarity description 
Sequence 
coverage 
Similarity 
percent 
Ph3 
- Leishmania donovani BPK282A1 complete genome 
- Leishmania infantum JPCM5 conserved hypothetical 
protein 
- Trypanosoma congolense IL3000 annotated genomic 
contig 
- Trichomonas vaginalis 
34% 
34% 
 
34% 
 
32% 
100% 
100% 
 
100% 
 
100% 
Ph23 
- Leishmania major strain Friedlin complete genome 
- Leishmania braziliensis MHOM/BR/75/M2904  
40% 
37% 
100% 
100% 
Ph5 - Trichomonas vaginalis G3 hypothetical protein 64% 95% 
Ph19 - Schistosoma mansoni 51% 100% 
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The DNA sequence similarity data analysis for Ph3 and Ph23 peptides is shown below. 
Species and DNA sequence similarity to clone Ph3: 
1- emb|FR799619.2| Leishmania donovani BPK282A1 complete genome, 
chromosome 32: hypothetical protein, conserved 
 
 Score = 32.2 bits (16),  Expect =   212 
 Identities = 16/16 (100%), Gaps = 0/16 (0%) 
 Strand=Plus/Minus 
 
Query  31       GCGGGTGGGTGGAGGT  46 
                |||||||||||||||| 
Sbjct  1102812  GCGGGTGGGTGGAGGT  1102797 
 
 
2- emb|HE575316.1|  Trypanosoma congolense IL3000 annotated genomic 
contig, chromosome 3: conserved hypothetical protein 
 
 Score = 32.2 bits (16),  Expect =   212 
 Identities = 16/16 (100%), Gaps = 0/16 (0%) 
 Strand=Plus/Plus 
 
Query  8       CAGAGTCGTAATTCTC  23 
               |||||||||||||||| 
Sbjct  616033  CAGAGTCGTAATTCTC  616048 
 
 
 
3- ref|XM_001467931.2|  Leishmania infantum JPCM5 conserved hypothetical 
protein (LINJ_32_2920) mRNA, complete cds 
 
 GENE ID: 5072032 LINJ_32_2920 | hypothetical protein 
[Leishmania infantum JPCM5] 
 
 Score = 32.2 bits (16),  Expect =   212 
 Identities = 16/16 (100%), Gaps = 0/16 (0%) 
 Strand=Plus/Plus 
 
Query  31    GCGGGTGGGTGGAGGT  46 
             |||||||||||||||| 
Sbjct  2588  GCGGGTGGGTGGAGGT  2603 
 
 
 
4- ref|XM_001308024.1|  Trichomonas vaginalis G3 hypothetical protein 
(TVAG_204370) partial mRNA  
GENE ID: 4752839 TVAG_204370 | hypothetical protein [Trichomonas 
vaginalis G3] 
 
 Score = 34.2 bits (17),  Expect =    54 
 Identities = 17/17 (100%), Gaps = 0/17 (0%) 
 Strand=Plus/Minus 
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Query  11   AGTCGTAATTCTCATGA  27 
            ||||||||||||||||| 
Sbjct  637  AGTCGTAATTCTCATGA  621 
 
 
Species and DNA sequence similarity to clone Ph23: 
 1- emb|FR796414.1|  Leishmania major strain Friedlin complete 
genome, chromosome 18 
 
 Score = 36.2 bits (18),  Expect =    13 
 Identities = 18/18 (100%), Gaps = 0/18 (0%) 
 Strand=Plus/Plus 
 
Query  19      CTTACGCCGGCGCCTTCG  36 
               |||||||||||||||||| 
Sbjct  432976  CTTACGCCGGCGCCTTCG  432993 
 
 
2- emb|FR799007.1|  Leishmania braziliensis MHOM/BR/75/M2904 complete 
genome, chromosome 32: conserved hypothetical protein 
 
 Score = 34.2 bits (17),  Expect =    52 
 Identities = 17/17 (100%), Gaps = 0/17 (0%) 
 Strand=Plus/Plus 
 
Query  19      CTTACGCCGGCGCCTTC  35 
               ||||||||||||||||| 
Sbjct  230149  CTTACGCCGGCGCCTTC  230165 
 
In order to provide more evidence for the relevance of Ph3 and Ph23 peptides to 
Leishmania parasites, the DNA nucleotide sequences was translated into amino acids 
according to protozoan codon translation standards and this was followed by protein 
BLAST similarity search.  
 
Table 6: Amino acid translation of Ph3 and Ph23 peptides based on their DNA sequence. 
Peptide 
Translated amino acid 
sequence 
Ph3 TRQSRNSHDMRV 
Ph23 KYMHAPLTPAPS 
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The BLAST similarity analysis shown below, sowed homology of the Ph3 peptides and 
Ph23 peptides to some leishmanial antigenic epitopes, at least six amino acids from each 
peptides was showed to be similar to known leishmnial proteins.  
 
Amino acid similarity to Ph3 peptide: 
1- XP_001469700.1|  conserved hypothetical protein [Leishmania infantum   
   emb|CBZ38746.1|  hypothetical protein, conserved [Leishmania donovani] 
 
 GENE ID: 5073804 LINJ_36_3080 | predicted zinc finger protein 
[Leishmania infantum JPCM5] 
 
Identities = 11/17 (65%), Positives = 11/17 (65%), Gaps = 3/17 (18%) 
 
Query  2    RQSRNSHDMRV---  15 
            RQ R S DMRV    
Sbjct  366  RQPRVSLDMRVPAA  382 
 
2- emb|CAM43204.2|  conserved hypothetical protein [Leishmania 
braziliensi 
   emb|CBZ37129.1|  hypothetical protein, conserved [Leishmania donovani] 
   emb|CBZ29781.1|  conserved hypothetical protein [Leishmania Mexican 
   ref|XP_001468073.1|  conserved hypothetical protein [Leishmania 
infantum 
   ref|XP_001685712.1|  conserved protein [Leishmania major] 
 
Identities = 7/9 (78%), Positives = 7/9 (78%), Gaps = 0/9 (0%) 
 
Query  2    RQSRNSHDM  10 
            RQ RN HDM 
Sbjct  654  RQVRNPHDM  662 
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Amino acid similarity to Ph23 peptide: 
1- ref|XP_001469372.1| hypothetical protein, [Leishmania infantum JPCM5] 
   emb|CAM72479.1| hypothetical protein, [Leishmania infantum JPCM5] 
 
  
 Identities = 11/23 (48%), Positives = 11/23 (48%), Gaps = 11/23 (48%) 
 
Query  4    HAPLTPAP-----------S  15 
            H PLTPAP           S 
Sbjct  185  HVPLTPAPPTSPPCSSRRAS  207 
 
 
 
2- emb|CBZ29642.1|  conserved hypothetical protein [Leishmania mexicana 
MHOM/GT/2001/U1103] 
 
Identities = 10/15 (67%), Positives = 10/15 (67%), Gaps = 3/15 (20%) 
 
Query  4    HAPLTPAPS---  15 
            H PLTP PS    
Sbjct  462  HTPLTPSPSSAA  476 
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Chapter Four: Discussion 
 
Infectioon caused by leishmania parsite in human is characterized by the appearance of 
anti-leishmnial antibodies in the sera of the patients with great variation in humoral 
immune response in VL and CL cases. In CL, antibodies are present at low level during the 
active phase of the disease (84). In contrast, high anti-leishmanial antibody titers are well 
detected in VL (85,86). The role of elevated anti-leishmanial antibodies in VL patients 
towards protection or disease is not clear. Analysis of leishmania antigen specific 
immunoglobulin isotypes revealed elevated levels of IgG, IgM, and IgE antibodies (87,88).  
IgG antibodies do not protect against intracellular pathogens (specifically against 
leishmania parasite) but it contributes to disease prognosis.  Since, passive administration 
of anti-leishmania IgG results in larger lesions in BALB/c mice with greater amount of IL-
10 production. And this can be linked to high elevation of antibody titer during active 
phase of infection, and fall in antibody titer after cure (89). 
 
Studies in human, dogs and mouse models,  have demonstrate that protective immunity 
against leishmania is  T cell mediated, while disease production is associated with the 
production of antibodies and absence of cell mediated immunity. In dogs leishmaniasis 
develops a humoral response but non-protective immune response. The increase in serum 
immunoglubulins appears to be due to polyclonal B cell activation (90). The dogs mainly 
produce IgG antibodies that can be detected in 1-4 months after parasite challenge. The 
relative level of IgG1 and IgG2 are prognostic indicators of cure and disease, associating 
IgG1 to the development of the disease and IgG2 to an asymptomatic infection (91).  
To emphasize the type of immune response against leishmania in mammalian hosts; the 
murine model using L. major and L. donovani are excellent studied experimental models to 
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demonstrate immunity against leishmaniasis.  BALB/c mice are highly susceptible to L. 
major infection and undergo progressive and fatal disease while L. major infection in 
humans is usually self-healing.  On the other hand, C57/bl6 and CBA/n mice are resistant 
to L. major infection, and develop small lesions that resolve(33,36). Mice are generally 
resistant to L. donovani infection and do not die of the disease, even though this parasite 
can cause fatal VL in humans (28,33,35).  The differences between infection in the 
experimental murine model and human infection are not completely related to host 
genetics but may also reflect differences in the size and nature of the infected parasite and 
route of infection (92). 
 
The progression of CL in the murine system, to disease or cure, is mainly regulated by T-
cell responses.  Infection of experimental mice with L. major promastigotes involves 
activation of CD4+ cells.  Upon challenge with L. major different mouse strains evoke 
varying immune responses, CD4+ T-helper type 1 (Th1) and type 2 (Th2), which are 
associated with different clinical outcomes.  The nature of the immune response, Th1/Th2, 
has been shown to determine the resistance or susceptibility of mice to Leishmania 
infection (93,94,95).  The CD4+ T-cell subsets can be distinguished by the cytokines they 
secrete.  Th1 cells secrete IL-2, IFN- and TNF- which activate cell-mediated immunity, 
while Th2 cells secrete cytokines such as IL-4, IL-5, IL-6, IL-9, IL-10, IL-13 and TGF- 
which promote antibody responses (96). Susceptible BALB/c mice characterized by Th2 
response and disease development.  IL-4 secreted by Th2 cells down-regulates the 
expression of IL-12 receptors on Th1 cells making them unresponsive to IL-12 inhibiting 
the production of IFN- and nitrogen oxide (97).  
In contrast to CL, less is known about the immunological mechanisms controlling the 
development of VL.  Immunity to L. donovani is dependent upon the effective generation 
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of cell-mediated immune mechanisms causing host macrophage activation to kill the 
intracellular parasites.  T cell depletion decreases the resistance in mice infected with L. 
donovani and the transfer of T cells from recovered mice protects naive mice from 
infection (98).  Patients with acquired immunodeficiency syndrome (AIDS) and other 
functional T-cell defects are highly susceptible to L. donovani infections. 
 
Epidemiological studies on human VL suggest that up to 85% of the infected individuals 
may spontaneously control infection.  Those individuals either remain asymptomatic or 
develop minor symptoms of infections that eventually resolve without treatment. This 
response is associated with skin test reactivity and appears to correlate with intact antigen-
specific production of IFN- (99).  The presence of IL-4 and IL-10, Th2 cell associated 
cytokines, appears important since both can suppress the secretion of activating cytokines, 
including IFN- and IL-2, which are important in host defense.  This suggests the 
possibility that Th2 activation may be involved in the progression of the human VL. 
 
There is no data about the epidemiology of visceral leishmaniasis in Palestine, except an 
old report from the Palestinian Ministry of Health indicating the presence of 53 VL cases 
in Hebron between 1994 to 2004. In another abstract the epidemiology of VL was reported 
to be  7.2 % in Beit Ola near Hebron based on ELISA serodiagnosis. Until now there is a 
missing accurate data about the epidemiology of VL cases in Palestine and in many cases it 
seems they are misdiagnosed for lack of experience. In this study all the obtained sera of 
VL cases showed high antibody titers, four out of the five cases were from Jenine. This 
indirectly indicates about the presence of active foci of VL in Jenine, and most probably all 
these cases are active infections that plays a major role in disease transmission. The results 
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of Western blot analysis are consistent with the known findings of VL and CL immune 
response. The pooled VL sera was able to detect high molecular bands of the crude 
leishmanial extracts, and as indicated the VL humoral response is a polyclonal in nature 
and it has the ability to detect many circulating or cellular lesihmaial antigens. The main 
antibody isotype in VL pooled sera is of IgG, and we could not detect an IgM antibody 
classes against Leishmanial crude antigens which is normally decline after a time of the 
infection.  
 
Phage display technology is a powerful method of epitope mapping that has been used to 
select peptides capable to mimic linear epitopes, nonlinear epitopes, and even non-protein 
molecules (100).  Different studies have been performed to determine whether mimotopes 
selected from phage display libraries by protective antibodies or antibodies against 
protective antigens could serve as the basis for a peptide vaccine or a diagnostic tool.  Two 
different phage display libraries were used to map the epitopes of a mAb against the ring-
infected erythrocyte surface antigen (RESA) of Plasmodium falciparum which is a vaccine 
candidate for malaria (101).   
 
In this study, we screened pIII random peptide phage display library (a 12-mer) with the 
VL pooled serum.  From a total of 35 reactive peptides with VL sera only 18 were 
sequenced and from those only four peptides showed similarity with known antigenic 
epitopes related to L . donovani the causative agent of VL.   This finding does not exclude 
the importance of the other obtained peptides; sequenced or not. This is because these 
peptides were bound specifically to antibodies from VL infected pool sera. In general most 
of the selected and sequenced peptides (13 out of 18) had no complete consensus linear 
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motif in common and no linear sequence identities with any currently known proteins or 
DNA sequences.  This fact may eliminate the role of these peptides as sequential epitopes 
but never as conformational epitopes or as mimitopes that mimic different antigenic 
proteins of similar amino acid composition, or carbohydrates that have similar 
conformational structure.   
 
The amino acid sequence composition of the obtained epitopes was determined by 
translating the nucleotide sequence based on protozoan standard codons. A comparison of 
the amino acid composition of these peptides in terms of exact sequence and or the type of 
the amino acids (acidic or basic amino acids, polar or non-polar amino acids) that form the 
epitope did not show any similarity among each other. This is is mainly related to the 
polyclonal antibody nature of the VL immune response against the leishmania parasite. On 
the other hand, 2 out of 4 peptides that showed similarity with known leishmania DNA 
sequences, also they showed high similarity at the protein level of these peptides with 
many antigenic determinants of leishmaial origins.  
Conclusion 
Phagotopes selected using one mAb may be specifically recognized by other antibodies, 
such as infected human sera, against the same determinant (102). Such peptides can act as 
diagnostic markers for the detection of disease related antibodies in patient sera.  In certain 
endemic regions total leishmanial crude antigen cannot be used for VL serodiagnosis 
because sera from other diseases, such as Chagas’ disease, cross-reacts with this antigen.  
The search for specific and sensitive diagnostic epitopes for use in VL assays has focused 
on pure and recombinant proteins (102).  In this sense the potential use of the identified 
peptides in serodiagnosis is one the important recommendations for the future work. This 
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will involved peptide synthesis, binding to large protein carrier and validation by testing 
these peptides with different VL sera in ELISA test.  
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Appendix A 
 
Peptides coding sequences of the 14 different clones identified by high antibody titer VL 
pooled sera. 
>Ph3 
ACTCGTCAGA GTCGTAATTC TCATGATATG CGGGTGGGTG GAGGT 
 
>Ph5 
AGTGTTCATA GTGAGAGGAG TAAGTTTCTG CGGAATGGTG GAGGT 
 
>Ph19 
GATCATCATG GGATGGTTCA TGCTGATCGG ATGATTGGTG GAGGT 
 
>ph20 
CTNCCTGNAT NGNAATCAGN AGACNAGGCN TAGTTTGGT GGAGGT 
 
>Ph22 
CATGGTATNT ATGNGNATAA TNAGACTCAG AAGCCTGGTG GAGGT 
 
>Ph23 
AAGTATATGC ATGCACCTCT TACGCCGGCG CCTTCGGGTG GAGGT 
 
>Ph24 
GGTCAGGGTA GTTCGTTTGG GTAGAATATG AAGCTTGGTG GAGGT 
 
>Ph25 
CCGGATNNTT TTNCAAANCC NANAGAGGNA CCGCCNGGTG GAGGT 
 
>Ph27 
TGGTGTGGTT ACGCATCTTT ATACGCCTTT GCCGCTGGT GGAGGT 
 
>Ph28 
CATATTACTA CGAGGACTAG TACTGTTGAG CGGAATGGTG GAGGT 
 
>Ph29 
ACGAATGAGA CTCGTACTGT GCGGCATATT CGGTTTGGTG GAGGT 
 
>Ph30 
TTGCCTCCTA TGTAGTTTAA GGTGGGGGCG CAGTTTGGTG GAGGT 
 
>Ph33 
AATATTCTTT ATGCAAATCA TTAAATTGTT CCTAATGGTG GAGGT 
 
>Ph34 
TAGGATCTTT TGGCAATTCC TTTAGTTGAT CCTTTGGGTG GAGGT 
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التعرف على المعلمات السطحية لطفيل الليشمانيا من خلال استخدام مصل 
 المصابين ذو التركيز العالي بالمضادات
 نسرين سعيد القاضي: إعداد
 
 عباسي إبراهيم. د:المشرف
 
 ملخص
 
واسعة الانتشار ويعد من المشاكل الصحية التي تعنى بها منظمة  الأمراضيعتبر داء الليشمانيا من 
دولة حول العالم و يهدد ما  88المتفشية في  الأمراضلعالمية، يعتبر مرض الليشمانيا من الصحة ا
 الليشمانيا يفيلطينتقل .  ر منظمة الصحة العالميةوفقا لتقاري بالإصابة امليون شخص 350يقارب 
ض يوجد مر. يةابة لضحيتها من الكائنات الفقارذبابة الرمل المص أنثىمن خلال لسع  العائل إلى
 .الجلدية المخاطية لليشمانيا الجلدية و الليشمانياالليشمانيا الحشوية و ا: وهي أشكالالليشمانيا بثلاثة 
 
  egahpالتعرف على المعلمات السطحية  لليشمانيا باستخدام تقنية العاثيات  إلىهدف هذه الدراسة ت
 أنواعدات و التي تحاكي لك للكشف و التعرف على البيبتيوذ  31Mمنها باستخدام النوع الخيطي
المناطق الناتجة من  أوseuqalp مى البلاكس سالمعلمات السطحية لطفيل الليشمانيا من خلال ما ي
لذا تم عمل مسح كامل . في ما يعرف مكتبة العاثيات أمينيحمض  12والمكونة من   العاثيات
والتي تم فحص  الجلديةنوعي الليشمانيا الحشوية و  من ميع العينات التي تم جمعها من كللج
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تركيز من مصول المرضى المصابين  الأعلىالنوعية لليشمانيا فيها و تحديد العينات ذات  الأضداد
من هذه العينات    sloopومن ثم تم تجميعها وعمل مجمعات  ASILEمن خلال تطبيق اختبار 
 .تركيز الأعلىذات 
ن عينات الليشمانيا الحشوية تم  عمل تركيز م الأعلىذات  sloopمن خلال استخدام التجمعات 
وتم الحصول  أمينيحمض  12المكونة من   egahpتي مسح لهذه العينات باستخدام العثيات ردو
  seuqalp 45من المسح الثاني تم الحصول على  أما  seuqalp 21على   الأولفي دورة المسح 
ت العينات من الليشمانيا تفاعل ايجابي قوي مع مجمعا  أعطت seuqalp 50منها ما يقارب 
تم استخدام   أمينيحمض  12من  المكونةوللتعرف على الشيفرة المكونة لهذه البيبتيدات . الحشوية
 sremirpالبارئاتباستخدام  تكثيرهو العمل على  31M egahpمن   0المكون لبروتين  0جين 
تم . RCPفحص   طبيقت ومن ثم   0لجين  المحيطة الأطرافوالتي تم تصميمها اعتمادا على 
ب من خلال لهذا الترتي التشابهمختلفة ومن ثم تم تحديد  senolc 52ل  قواعديتحديد الترتيب ال
ربعة سميت كما يلي أتم تحديد  52 ضمنومن  مورثاتعمل بحث في بنك ال
وأصناف أخرى   inavonod ainamhsieLعتشابها عاليا م لإظهارها  32hP,91hP,5hP,3hP
 sunomohcirT dna amosonapyrT( (السوط تحديدا ذات توغيرها من الطفيليا امن الليشماني
والمعروف بدايته  0عليها وتحديدها على موقعها في جين التي تم التعرف البيبتيداتهذه  إدخالتم . 
 قد تبين أنالذكر تم ترجمتها و أنفة  senolc المستنسخات الأربعةوهذه . ونهايته من النيوكليوتيدات
 ainamhsieL ل المميزةتشابها كبيرا مع المعلمات  أظهرت   32hP , 3hPين منها وهي اثن
  sepotipeتصنيع هذه المعلمات ل ألتحليلهالتجارب  عمل وهذا يمهد مستقبلا إلى inavonod
 .لقاح لليشمانيا الحشوية إيجادواستخدامها في التشخيص بهدف 
